Clinical trial · Interventional
PIPAC for the Treatment of Colorectal Peritoneal Metastases
Pilot Study Assessing the Efficacy of Oxaliplatin Based Pressurised IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the Treatment of Colorectal Peritoneal Metastases
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study would like to assess the efficacy of pressurised intraperitoneal aerosol chemotherapy (PIPAC). This technique delivers chemotherapy directly into the abdomen via a less invasive laparoscopic or 'keyhole' form of surgery. This type of chemotherapy takes the form of an aerosol, similar to the spray of a deodorant for example. The aerosol is administered into the abdomen under pressure, pushing the chemotherapy deeper into the tissues and cancer. This approach does not involve any surgical removal of the cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Neoplasms | Colorectal Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Peritoneal Metastases | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment with PIPAC
- description
- Patients with colorectal cancer and peritoneal metastases being treated with pressurised intraperitoneal aerosol chemotherapy (PIPAC)
- interventionNames
- Procedure: Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC)
Primary outcomes (1)
- measure
- Progression free survival assessed by laparoscopy and cross sectional imaging
- timeFrame
- 2 year follow up or until death
Secondary outcomes (3)
- measure
- Quality of life assessments - QLQ-C30 questionnaire
- timeFrame
- Repeated 6-8 weekly before each PIPAC treatment. Trend correlated over period of trial until end of September 2021 and reported thereafter
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with CPM with expected life expectancy of \> 6 months. 2. ECOG Scale of Performance Status (PS) scores 0 or 1. 3. 15 mile catchment area to facilitate overseeing systemic chemotherapy administration 4. Concomitant systemic chemotherapy regimens with FOLFIRI, FOLFOX, Mitomycin C \& Fluorouracil, Capecitabine (excluding Lonsurf) or without systemic chemotherapy if no systemic options available to patient 5. Neutrophil count on or just before chemotherapy due date of \>1.5 Exclusion Criteria: 1. Age \<18 2. MDT decision that patient not suitable for PIPAC 3. Decision by Preoperative Assessment Department or Consultant Anaesthetist that patient not fit for general anaesthesia and / or laparoscopy 4. Clinically evident gross ascites 5. Bowel obstruction 6. Bevacizumab as part of systemic chemotherapy regime - time from chemotherapy to surgery would be too long for PIPAC to be feasible 7. Previous bone marrow suppression due to chemotherapy given risk of post-operative neutropenia
References
Publications (0)
Data not yet available